Last reviewed · How we verify
Curcumin (Turmeric) — Competitive Intelligence Brief
phase 3
Natural polyphenol / anti-inflammatory agent
NF-κB, multiple cytokines (TNF-α, IL-6, IL-8), reactive oxygen species
Inflammation, Oncology, Gastrointestinal, Rheumatology
Small molecule
Live · refreshed every 30 min
Target snapshot
Curcumin (Turmeric) (Curcumin (Turmeric)) — Services Institute of Medical Sciences, Pakistan. Curcumin inhibits multiple inflammatory pathways and transcription factors, particularly NF-κB, reducing pro-inflammatory cytokine production and oxidative stress.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Curcumin (Turmeric) TARGET | Curcumin (Turmeric) | Services Institute of Medical Sciences, Pakistan | phase 3 | Natural polyphenol / anti-inflammatory agent | NF-κB, multiple cytokines (TNF-α, IL-6, IL-8), reactive oxygen species |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Natural polyphenol / anti-inflammatory agent class)
- Services Institute of Medical Sciences, Pakistan · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Curcumin (Turmeric) CI watch — RSS
- Curcumin (Turmeric) CI watch — Atom
- Curcumin (Turmeric) CI watch — JSON
- Curcumin (Turmeric) alone — RSS
- Whole Natural polyphenol / anti-inflammatory agent class — RSS
Cite this brief
Drug Landscape (2026). Curcumin (Turmeric) — Competitive Intelligence Brief. https://druglandscape.com/ci/curcumin-turmeric. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab